Pharmacy Heroes: Infectious Disease Pharmacists Care for Patients with COVID-19
Today, we’re thanking Dustin Linn, PharmD, RPh, BCCCP, and Trent Towne, PharmD, RPh, BCPS (AQID), for their work treating patients with COVID-19.
Related Articles
Identifying and Screening for Hepatic Encephalopathy Risk Factors
Arun Jesudian, MD; Ralph J. Riello, PharmD, BCPS, and Chas McCormick, RPh, MBA, delve into the complexities of hepatic encephalopathy, exploring the various risk factors…
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
IMPACT CKD, a modeling analysis created by AstraZeneca, includes data about chronic kidney disease across 8 countries, including the United States.
FDA Approves Ustekinumab Biosimilar to Stelara for Treatment of Plaque Psoriasis
Ustekinumab (Stelara; Janssen Immunology) is a human monoclonal antibody that treats immune-mediated diseases such as psoriasis and psoriatic arthritis.
Tirzepatide Demonstrates Reduction in Sleep Apnea-Relate Events
Eli Lilly and Company will submit results of the study to support tirzepatide (Zepbound) for treatment of obstructive sleep apnea later this year.
Semaglutide’s New Indication Highlights Growing Role of GLP-1 Receptor Agonists
The latest FDA approval paves the way for expanded use of GLP-1 receptor agonists in patients without diabetes.
Study Details Benefits, Therapeutic Effects of Medical Marijuana on Patients’ Quality of Life
The study is the first of 5 studies co-published by AYR Wellness and LECOM and showcases improvements in physical, social, and mental well-being with minimal…
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
AI offers many benefits in health professions by efficiently handling time-consuming tasks crucial for patient care.
FDA Grants Breakthrough Device Designation to Assay Supporting Earlier Diagnosis of Alzheimer Disease
If approved, the test could provide more timely and accurate diagnosis, hopefully mitigating the impact of Alzheimer disease (AD) on individuals and the community.
Study Finds No Differences Between Adalimumab, Biosimilar for Inflammatory Bowel Disease
There was no difference observed between adalimumab (Humira; AbbVie) and adalimumab-aacf (Idacio; Fresenius Kabi) for those who switched to the biosimilar.